Denali Therapeutics Inc. Revenue
Denali Therapeutics Inc. (DNLI) reported Revenue of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Income Statement › Revenue
us-gaap:Revenues · last filed 2026-02-26
- Denali Therapeutics Inc. revenues for the quarter ending 2024-03-31 was $0.00, a 100.00% decline year-over-year.
- Denali Therapeutics Inc. revenues for the quarter ending 2023-12-31 was $0.00, a 100.00% decline year-over-year.
- Denali Therapeutics Inc. revenues for the quarter ending 2023-09-30 was $1.27M, a 64.40% decline year-over-year.
- Denali Therapeutics Inc. revenues for the quarter ending 2023-06-30 was $294.12M, a 460.45% increase year-over-year.
- Denali Therapeutics Inc. revenues for fiscal 2025 was $0.00.
- Denali Therapeutics Inc. revenues for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- Denali Therapeutics Inc. revenues for fiscal 2023 was $330.53M, a 204.74% increase from fiscal 2022.
- Denali Therapeutics Inc. revenues for fiscal 2022 was $108.46M, a 122.90% increase from fiscal 2021.
| Period end | Revenues 3 month | Revenues 6 month | Revenues 9 month | Revenues 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-26 | |||
| 2024-12-31 | $0.00 10-K · filed 2026-02-26 | |||
| 2024-03-31 | $0.00 10-Q · filed 2024-05-07 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $1.27M derived: sum of 3 quarters · filed 2026-02-26 | $295.39M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.27M derived: sum of 2 quarters · filed 2026-02-26 | $295.39M derived: sum of 3 quarters · filed 2026-02-26 | $330.53M 10-K · filed 2026-02-26 |
| 2023-09-30 | $1.27M 10-Q · filed 2023-11-07 | $295.39M derived: sum of 2 quarters · filed 2023-11-07 | $330.53M 10-Q · filed 2023-11-07 | $340.81M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $294.12M 10-Q · filed 2023-08-08 | $329.26M 10-Q · filed 2023-08-08 | $339.55M derived: sum of 3 quarters · filed 2025-02-27 | $343.11M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $35.14M 10-Q · filed 2024-05-07 | $45.42M derived: sum of 2 quarters · filed 2025-02-27 | $48.98M derived: sum of 3 quarters · filed 2025-02-27 | $101.46M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $10.28M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $13.84M derived: sum of 2 quarters · filed 2025-02-27 | $66.32M derived: sum of 3 quarters · filed 2025-02-27 | $108.46M 10-K · filed 2025-02-27 |
| 2022-09-30 | $3.56M 10-Q · filed 2023-11-07 | $56.04M derived: sum of 2 quarters · filed 2023-11-07 | $98.18M 10-Q · filed 2023-11-07 | $110.69M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $52.48M 10-Q · filed 2023-08-08 | $94.62M 10-Q · filed 2023-08-08 | $107.14M derived: sum of 3 quarters · filed 2024-02-28 | $112.42M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $42.14M 10-Q · filed 2023-05-08 | $54.66M derived: sum of 2 quarters · filed 2024-02-28 | $59.94M derived: sum of 3 quarters · filed 2024-02-28 | $82.88M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $12.51M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $17.80M derived: sum of 2 quarters · filed 2024-02-28 | $40.74M derived: sum of 3 quarters · filed 2024-02-28 | $48.66M 10-K · filed 2024-02-28 |
| 2021-09-30 | $5.29M 10-Q · filed 2022-11-03 | $28.22M derived: sum of 2 quarters · filed 2022-11-03 | $36.15M 10-Q · filed 2022-11-03 | $352.96M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | $22.94M 10-Q · filed 2022-08-08 | $30.86M 10-Q · filed 2022-08-08 | $347.68M derived: sum of 3 quarters · filed 2023-02-27 | $357.07M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | $7.92M 10-Q · filed 2022-05-05 | $324.74M derived: sum of 2 quarters · filed 2023-02-27 | $334.13M derived: sum of 3 quarters · filed 2023-02-27 | $339.98M derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | $316.81M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $326.21M derived: sum of 2 quarters · filed 2023-02-27 | $332.06M derived: sum of 3 quarters · filed 2023-02-27 | $335.66M 10-K · filed 2023-02-27 |
| 2020-09-30 | $9.39M 10-Q · filed 2021-11-04 | $15.24M derived: sum of 2 quarters · filed 2021-11-04 | $18.84M 10-Q · filed 2021-11-04 | $23.52M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $5.85M 10-Q · filed 2021-08-04 | $9.45M 10-Q · filed 2021-08-04 | $14.12M derived: sum of 3 quarters · filed 2022-02-28 | $27.73M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $3.60M 10-Q · filed 2021-05-05 | $8.28M derived: sum of 2 quarters · filed 2022-02-28 | $21.88M derived: sum of 3 quarters · filed 2022-02-28 | $26.08M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | $4.67M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $18.28M derived: sum of 2 quarters · filed 2022-02-28 | $22.47M derived: sum of 3 quarters · filed 2022-02-28 | $26.68M 10-K · filed 2022-02-28 |
| 2019-09-30 | $13.60M 10-Q · filed 2020-11-05 | $17.80M derived: sum of 2 quarters · filed 2020-11-05 | $22.01M 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $4.20M 10-Q · filed 2020-08-07 | $8.40M 10-Q · filed 2020-08-07 | ||
| 2019-03-31 | $4.21M 10-Q · filed 2020-05-07 | |||
| 2018-12-31 | $129.16M 10-K · filed 2021-02-26 | |||
| 2018-03-31 | $641.00K 10-Q · filed 2018-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |